Literature DB >> 34247536

Systemic Immune-Inflammation Index May Predict the Development of Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction.

Ali Bağcı1, Fatih Aksoy1, Hasan Aydin Baş2.   

Abstract

The aim of this study was to investigate the predictive capacity of a systemic immune-inflammation index (SII) in the detection of contrast-induced nephropathy (CIN) following ST-segment elevation myocardial infarction (STEMI). A total of 477 STEMI patients were enrolled in the study. The patients were divided into 2 groups according to CIN development. A cutoff point of 5.91 for logarithm-transformed SII was identified with 73.0% sensitivity and 57.5% specificity to predict CIN following STEMI. According to a pairwise analysis of receiver operating characteristic curve analysis, the predictive power of SII in detecting CIN following STEMI was similar to that of high-sensitivity C-reactive protein and better than the neutrophil/lymphocyte ratio or platelet/lymphocyte ratio. As a result, SII can be used as one of the independent predictors of CIN after STEMI.

Entities:  

Keywords:  ST-segment elevation myocardial infarction; contrast-induced nephropathy; systemic immune-inflammation index

Mesh:

Substances:

Year:  2021        PMID: 34247536     DOI: 10.1177/00033197211030053

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

1.  Preprocedural SII Combined with High-Sensitivity C-Reactive Protein Predicts the Risk of Contrast-Induced Acute Kidney Injury in STEMI Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Kai Ma; Hang Qiu; Yinghua Zhu; Yuan Lu; Wenhua Li
Journal:  J Inflamm Res       Date:  2022-06-25

2.  Systemic Immune-Inflammation Index Predicts Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Cross-Sectional Study.

Authors:  Hangpan Jiang; Duanbin Li; Tian Xu; Zhezhe Chen; Yu Shan; Liding Zhao; Guosheng Fu; Yi Luan; Shudong Xia; Wenbin Zhang
Journal:  Front Med (Lausanne)       Date:  2022-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.